Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.30 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL360055 | 0.99 | KMT2A (0.34) | KMT2APDE4BOPRM1ALDH1A1PLA2G1B | |
| SCHEMBL359944 | 0.89 | KMT2A (0.35) | KMT2AALDH1A1MEN1NPC1RAB9A | |
| SCHEMBL360883 | 0.88 | ALDH1A1 (0.36) | KMT2AALDH1A1MEN1NPC1RAB9A | |
| SCHEMBL10080379 | 0.86 | HTR2C (0.38) | PDE4BOPRM1 | |
| SCHEMBL10080298 | 0.85 | HTR2C (0.40) | KMT2APDE4BOPRM1ALDH1A1PLA2G1B | |
| SCHEMBL15344568 | 0.82 | ALDH1A1 (0.30) | ALDH1A1PLA2G1BNPSR1ATG4B | |
| SCHEMBL15344561 | 0.81 | ALDH1A1 (0.32) | ALDH1A1PLA2G1BNPSR1ATG4B | |
| SCHEMBL360216 | 0.79 | TP53 (0.33) | ALDH1A1 | |
| SCHEMBL359609 | 0.78 | — | — | |
| SCHEMBL15344567 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11312688-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-04-26 | — | — | US | disclosed |
| US-20200308119-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2020-10-01 | — | — | US | disclosed |
| US-10723703-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-07-28 | — | — | US | disclosed |
| US-20190084938-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2019-03-21 | — | — | US | disclosed |
| US-10183913-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-01-22 | — | — | US | disclosed |
| US-10087146-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-10-02 | — | — | US | disclosed |
| US-20180273489-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2018-09-27 | — | — | US | disclosed |
| US-20170217902-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2017-08-03 | — | — | US | disclosed |
| US-9663472-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-05-30 | — | — | US | disclosed |
| EP-2594559-B1 | PYRAZOLE COMPOUND | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2016-02-24 | — | — | EP | disclosed |
| US-20140315971-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2014-10-23 | — | — | US | disclosed |
| US-20140031406-A1 | PYRAZOLE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| EP-2594559-A1 | PYRAZOLE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2013-05-22 | — | — | EP | disclosed |
| US-20130116296-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2013-05-09 | — | — | US | disclosed |
| WO-2012008528-A1 | PYRAZOLE COMPOUND | 大日本住友製薬株式会社 (JP) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315971-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | KMT2A 2238/4885PDE4B 1680/4885OPRM1 129/4885 |
| US-10183913-B2 | Pyrazole compound | HTR2C, HTR3B, HTR3A | KMT2A 2238/4885PDE4B 1680/4885OPRM1 129/4885 |
| US-20170217902-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | KMT2A 2238/4885PDE4B 1680/4885OPRM1 129/4885 |
| US-11312688-B2 | Pyrazole compound | HTR2C, HTR3B, HTR3A | KMT2A 2238/4885PDE4B 1680/4885OPRM1 129/4885 |
| US-20130116296-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | KMT2A 2238/4885PDE4B 1680/4885OPRM1 129/4885 |
| US-20200308119-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | KMT2A 2238/4885PDE4B 1680/4885OPRM1 129/4885 |
| US-10723703-B2 | Pyrazole compound | HTR2C, HTR3B, HTR3A | KMT2A 2238/4885PDE4B 1680/4885OPRM1 129/4885 |
| US-20180273489-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | KMT2A 2238/4885PDE4B 1680/4885OPRM1 129/4885 |
| US-20190084938-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | KMT2A 2238/4885PDE4B 1680/4885OPRM1 129/4885 |
| US-10087146-B2 | Pyrazole compound | HTR2C, HTR3B, HTR3A | KMT2A 2238/4885PDE4B 1680/4885OPRM1 129/4885 |
| US-20140031406-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | KMT2A 2238/4885PDE4B 1680/4885OPRM1 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.